Related Experiment Videos

Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five

E Malacco1

  • 1III Division of Internal Medicine, "L. Sacco" Hospital, Milan, Italy. ettore.malacco@tiscali.it

European Review for Medical and Pharmacological Sciences
|June 19, 2010
PubMed

Insights

The nebivolol/hydrochlorothiazide combination effectively lowers blood pressure in real-world settings, including diabetic and elderly patients. This hypertension treatment is well-tolerated and shows significant reductions in both systolic and diastolic blood pressure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Nebivolol is a third-generation beta-blocker with distinct pharmacological properties.
  • The combination of nebivolol and hydrochlorothiazide (HCTZ) has been previously evaluated in clinical trials.
  • This study assesses the real-world effectiveness of nebivolol/HCTZ in a post-marketing surveillance analysis.

Purpose of the Study:

  • To evaluate the effectiveness of nebivolol/HCTZ in a real-life setting.
  • To assess the efficacy in specific patient subgroups, including those with diabetes and the elderly.
  • To monitor for any significant alterations in laboratory parameters.

Main Methods:

  • Data from five non-interventional German studies (up to 12 weeks) were pooled.
  • Patients received nebivolol/HCTZ 5/12.5 mg/day.
  • Changes in diastolic blood pressure (DBP) and systolic blood pressure (SBP), responder rates, and laboratory parameters were analyzed.

Main Results:

  • Nebivolol/HCTZ significantly reduced DBP (-11.8 mmHg) and SBP (-22.5 mmHg) compared to baseline (p<0.0001).
  • Overall responder rate was 81.4%, with 75% in elderly and 83.3% in diabetic patients.
  • No clinically significant alterations in laboratory parameters were observed.

Conclusions:

  • Nebivolol/HCTZ is an effective and well-tolerated treatment for hypertension in real-world clinical practice.
  • The combination therapy demonstrated efficacy comparable to clinical trial findings.
  • Nebivolol/HCTZ may be considered a first-choice therapy for hypertension management.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...